The content should be medically relevant and adhere docstop content guidelines . Docstop doesn’t support any brand related promotional activities

Share articles, case studies and web videos

Method : start a topic- select private, add group, give name, add email ids, and send to your selected group


11 May | Categories : COVID-19 (NEW) Start a topic Comment Mail Share Download


11 May | Categories : COVID-19 (NEW) Start a topic Comment Mail Share Download


11 May | Categories : COVID-19 (NEW) Start a topic Comment Mail Share Download


11 May | Categories : COVID-19 (NEW) Start a topic Comment Mail Share Download


11 May | Categories : COVID-19 (NEW) Start a topic Comment Mail Share Download
Background

Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir–ritonavir, and ribavirin for treating patients with COVID-19.

Methods

This was a multicentre, prospective, open-label, randomised, phase 2 trial in adults with COVID-19 who were admitted to six hospitals in Hong Kong. Patients were randomly assigned (2:1) to a 14-day combination of lopinavir 400 mg and ritonavir 100 mg every 12 h, ribavirin 400 mg every 12 h, and three doses of 8 million international units of interferon beta-1b on alternate days (combination group) or to 14 days of lopinavir 400 mg and ritonavir 100 mg every 12 h (control group). The primary endpoint was the time to providing a nasopharyngeal swab negative for severe acute respiratory syndrome coronavirus 2 RT-PCR, and was done in the intention-to-treat population. The study is registered with ClinicalTrials.govNCT04276688.

Findings

Between Feb 10 and March 20, 2020, 127 patients were recruited; 86 were randomly assigned to the combination group and 41 were assigned to the control group. The median number of days from symptom onset to start of study treatment was 5 days (IQR 3–7). The combination group had a significantly shorter median time from start of study treatment to negative nasopharyngeal swab (7 days [IQR 5–11]) than the control group (12 days [8–15]; hazard ratio 4·37 [95% CI 1·86–10·24], p=0·0010). Adverse events included self-limited nausea and diarrhoea with no difference between the two groups. One patient in the control group discontinued lopinavir–ritonavir because of biochemical hepatitis. No patients died during the study.

">


11 May | Categories : COVID-19 (NEW) Start a topic Comment Mail Share Download


12 Jun | Categories : COVID-19 (NEW) Start a topic Comment Mail Share Download


2 Mar | Categories : COVID-19 (NEW) Start a topic Comment Mail Share Download
World Pharma Conference 2021  an extensive range of critically important sessions from basic research to recent innovations. The theme: Exploring the latest research in Pharma and Biopharma” is designed for professionals at all levels and career phases of the Pharma industry, who want to improve their understanding of what will drive and shape the future of the market. 

We would like to invite you to the upcoming conference on “10th Edition of International Conference on World Pharmaceutical Sciences & Drug Delivery” Which is going to be held on August 26-27, 2021 at London, UK.

Abstract Link: https://worldpharmaconference.euroscicon.com/abstract-submission

Registration Link: https://worldpharmaconference.euroscicon.com/registration

Online Registrations and Abstract submission are open.  Submit your abstract and confirm your slot.

If you are interested write to:  annezivor17@gmail.com

Benefits for Conference:•     

1. Keynote certificate / speaker Certificate

2. CPD certificate / CME certificate

3. Best speaker / best young researcher award

4. Journal Publication with ISSN number

5. Separate Biography and research page in website.

6. Conference Kit

7. Lunch and breakfast.

">